Expert Interview
A third look: Discussing TECVAYLI (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
Ticker(s): JNJInstitution: Fred Hutchinson Cancer Research Center & Univ. of Washington
- Hematologist and Medical Oncologist at Fred Hutch & Associate Professor, Department of Medical Oncology.
- Treats 100 patients with CLL and 60 patients with r/r DLBCL.
- Research focuses on improving outcome for patients with multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin's disease using autologous transplant techniques.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
